FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer

FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.

from Cancer via ola Kala on Inoreader http://ift.tt/2B65btj
via IFTTT